<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03614793</url>
  </required_header>
  <id_info>
    <org_study_id>111315</org_study_id>
    <nct_id>NCT03614793</nct_id>
  </id_info>
  <brief_title>A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves Versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome</brief_title>
  <official_title>A Prospective Trial of Cooled Radiofrequency Ablation of Medial Branch Nerves Versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chronic, non-neurogenic low back pain (CLBP) is a common condition that affects many&#xD;
      individuals across their lives. The lumbar facet joint has been implicated as an important&#xD;
      source of CLBP, with a prevalence of 15-45%. Elements of clinical history, physical&#xD;
      examination, and imaging (radiographs, standard CT scan, standard MRI sequences) provide poor&#xD;
      diagnostic specificity for pain of lumbar zygapophysial joint (Z-joint) origin. Thus,&#xD;
      clinicians have traditionally relied upon MBN blocks to confirm or refute this diagnosis. The&#xD;
      reference standard for the diagnosis of lumbar Z-joint pain is a positive response to dual&#xD;
      comparative MBN blocks, which requires pain reduction of great than or equal to 80% of&#xD;
      concordant duration to that expected of two different local anesthetics on independent&#xD;
      occasions. Further, dual comparative MBN blocks have a high positive predictive value for&#xD;
      determining the clinical outcome of lumbar MBN RFA for the treatment of lumbar Z-joint pain;&#xD;
      when patients are appropriately selected using this reference standard and rigorous MBN RFA&#xD;
      technique is implemented according to practice guidelines, studies demonstrate excellent&#xD;
      clinical outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic, non-neurogenic low back pain (CLBP) is a common condition that affects many&#xD;
      individuals across their lives. The lumbar facet joint has been implicated as an important&#xD;
      source of CLBP, with a prevalence of 15-45%. Elements of clinical history, physical&#xD;
      examination, and imaging (radiographs, standard CT scan, standard MRI sequences) provide poor&#xD;
      diagnostic specificity for pain of lumbar zygapophysial joint (Z-joint) origin. Thus,&#xD;
      clinicians have traditionally relied upon MBN blocks to confirm or refute this diagnosis. The&#xD;
      reference standard for the diagnosis of lumbar Z-joint pain is a positive response to dual&#xD;
      comparative MBN blocks, which requires pain reduction of great than or equal to 80% of&#xD;
      concordant duration to that expected of two different local anesthetics on independent&#xD;
      occasions. Further, dual comparative MBN blocks have a high positive predictive value for&#xD;
      determining the clinical outcome of lumbar MBN RFA for the treatment of lumbar Z-joint pain;&#xD;
      when patients are appropriately selected using this reference standard and rigorous MBN RFA&#xD;
      technique is implemented according to practice guidelines, studies demonstrate excellent&#xD;
      clinical outcomes.&#xD;
&#xD;
      In additional to MBN RFA, lumbar facet joint injection of corticosteroid is another commonly&#xD;
      used treatment strategy for lumbar facet joint pain related to osteoarthritis. While clinical&#xD;
      outcome studies of facet joint injection with corticosteroid have generally shown only modest&#xD;
      outcome improvements, this literature is generally flawed by invalid selection protocols that&#xD;
      do not require dual comparative MBN blocks in order to confirm the diagnosis of pain specific&#xD;
      to the lumbar facet joint(s).&#xD;
&#xD;
      Despite the widespread use of these two techniques (lumbar MBN RFA vs. facet joint&#xD;
      corticosteroid injection), the two techniques have never been compared in an&#xD;
      appropriately-designed head-to-head study. The sole outcome study comparing these two&#xD;
      treatment methods used an invalid selection protocol of one positive MBN block, requiring&#xD;
      only 50% relief in pain and not of concordant duration with that expected by the local&#xD;
      anesthetic used; in addition, a single RFA lesion was applied with a 20g conventional RFA&#xD;
      electrode and fluoroscopic images were not published, so it is unclear if parallel electrode&#xD;
      technique was used, as is necessary with conventional RFA. This invalid patient selection and&#xD;
      RFA technique protocol is similar to that used in the Mint Trials, which has led to a broad&#xD;
      call for improving such standards in research and clinical care by a multitude of experts&#xD;
      representing interventional pain, spine, and radiology specialty societies. As such, an&#xD;
      appropriately designed head-to-head trial in warranted.&#xD;
&#xD;
      Furthermore, while the conventional RFA modality has been studied extensively for MBN RFA,&#xD;
      minimal outcome literature on the effectiveness of C-RFA technology has been published. C-RFA&#xD;
      is similar in mechanism to conventional RFA: a thermal lesion is created by applying&#xD;
      radiofrequency energy through an electrode placed at a target structure. In C-RFA, a constant&#xD;
      flow of ambient water is circulated through the electrode via a peristaltic pump, maintaining&#xD;
      a lowered tissue temperature by creating a heat sink. By removing heat from tissues&#xD;
      immediately adjacent to the electrode tip, a lower lesioning temperature is maintained,&#xD;
      resulting in less tissue charring adjacent to the electrode, less tissue impedance and more&#xD;
      efficient heating of target tissue. The volume of tissue heated, and the resultant thermal&#xD;
      lesion size is substantially larger with C-RFA, conferring an advantage over conventional&#xD;
      RFA. Further, given the spherical geometry and forward projection the C-RFA lesions beyond&#xD;
      the distal end of the electrode, the RFA probe can be positioned at a range of possible&#xD;
      angles and still capture the target neural structure, whereas more fastidious, parallel&#xD;
      positioning is required with conventional RFA. These technical advantages increase the&#xD;
      probability of successful denervation of neural pain generators that have variability in&#xD;
      anatomic location, as is the case with facet syndromes in which significant osteoarthritis is&#xD;
      present, which is associated with joint hypertrophy and osteophyte formation. Additionally, a&#xD;
      longer lesion of the MBN may be more reliably achieved with C-RFA compared to conventional&#xD;
      RFA, potentially resulted in greater treatment durability, as the recurrent of facetogenic&#xD;
      pain after successful denervation is related to reinnervation by nerve re-growth to bridge&#xD;
      the gap created by the lesion. Consistent with this technical advantage, there is preliminary&#xD;
      evidence for superiority of C-RFA compared to both conventional RFA and other novel RFA&#xD;
      techniques in the treatment of sacroiliac joint-mediated pain.&#xD;
&#xD;
      Lumbar facet joint pain is a common and costly cause of chronic low back pain. Lumbar MBN RFA&#xD;
      and facet joint injection of steroid are two commonly used treatment strategies for lumbar&#xD;
      facet-mediated pain, yet the two techniques have never been compared in an&#xD;
      appropriately-designed head-to-head trial. Further there is minimal clinical outcome&#xD;
      literature describing the effectiveness of MBN C-RFA despite its technical advantages over&#xD;
      conventional MBN RFA. We will determine if individuals with lumbar facet syndrome who are&#xD;
      treated with MBN C-RFA compared to face joint injection of corticosteroid have a greater&#xD;
      likelihood of experiencing meaningful relief of low back pain symptoms, functional&#xD;
      improvement, and reduction of analgesic medication use at both short and long-term follow-up.&#xD;
      Answering this clinical question will help determine which standard of care technique is&#xD;
      superior, such that patients with lumbar facet syndrome can get be offered the best treatment&#xD;
      available.&#xD;
&#xD;
      As such, the goal of the proposed study is to determine if individuals with lumbar facet&#xD;
      syndrome who are treated with C-RFA of the MBNs compared to face joint injection of&#xD;
      corticosteroid have a greater likelihood of experiencing meaningful relief of low back pain&#xD;
      symptoms, functional improvement, and reduction of analgesic medication use at both short and&#xD;
      long-term follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the proportion of patients with a successful response to lumbar MBN C-RFA versus facet joint injection of corticosteroid.</measure>
    <time_frame>2 years</time_frame>
    <description>The primary outcome for the randomized trial is the proportion of responders, defined by a reduction in NPRS score â‰¥50% at the 3-month follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical function (ODI and PF CAT)</measure>
    <time_frame>2 years</time_frame>
    <description>The ODI and PF CAT are two validated survey-based measures of physical function and how low back pain may affect physical function/functional disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global function (Global-10)</measure>
    <time_frame>2 year</time_frame>
    <description>The Global-10 is a validated survey-based assessment tool of global functioning that includes symptoms, function, and health care related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic use (MQS III score)</measure>
    <time_frame>2 year</time_frame>
    <description>Evaluate changes in opioid and non-opioid analgesic use in both groups, as assessed by the conversions to daily morphine equivalent use and Medication Quantification Scale III score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression of change (PGIC)</measure>
    <time_frame>2 year</time_frame>
    <description>PGIC survey-based assessment of subjective improvement in overall symptoms. This scale evaluates all aspects of patients' health and assesses if there has been an improvement or decline in clinical status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 year</time_frame>
    <description>Report immediate, short-term, and long-term adverse effects, using a standardized survey that includes a comprehensive query of known adverse events associated with systemic steroid effects</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Lumbar Facet Syndrome</condition>
  <arm_group>
    <arm_group_label>Cooled Radiofrequency Ablation Procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Facet Joint Inject Procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cooled Radiofrequency Ablation of Medial Branch Nerves versus Facet Joint Injection of Corticosteroid for the Treatment of Lumbar Facet Syndrome</intervention_name>
    <description>Radio frequency ablation (RFA) is a medical procedure in which heat is generated from high frequency electrical current in order to lesion (burn) nervous tissue.</description>
    <arm_group_label>Cooled Radiofrequency Ablation Procedure</arm_group_label>
    <arm_group_label>Facet Joint Inject Procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients aged &gt; 40 capable of understanding and providing consent in English and&#xD;
             capable of complying with the outcome instruments used.&#xD;
&#xD;
          -  Axial (non-radicular) back pain for at least 3 months (ie Chronic Low Back Pain), with&#xD;
             pain lasting at least half of the days within those 3 months, that did not respond to&#xD;
             conventional treatment such as physical therapy, oral analgesic agents, and&#xD;
             non-invasive adjunctive treatments. The pain can be unilateral or bilateral. The pain&#xD;
             can also include referred lower limb pain.&#xD;
&#xD;
          -  7-day worst numeric pain rating score (NPRS) for back pain of 5/10 or greater at&#xD;
             baseline evaluation.&#xD;
&#xD;
          -  Positive responses to dual comparative diagnostic MBN blocks using 0.5mL of 0.5%&#xD;
             bupivacaine and 4% lidocaine, on respective encounters on separate days, at each of&#xD;
             the appropriate MBNs. The blocks are administered in a double-blind fashion so that&#xD;
             neither the subject nor the independent assessor is aware of the local anesthetic&#xD;
             used.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Focal neurologic signs or symptoms.&#xD;
&#xD;
          -  Radiologic evidence of a symptomatic herniated disc or nerve root impingement related&#xD;
             to spinal stenosis.&#xD;
&#xD;
          -  Active systemic or local infections at the site of proposed needle and electrode&#xD;
             placement.&#xD;
&#xD;
          -  Coagulopathy or other bleeding disorder.&#xD;
&#xD;
          -  Receipt of remuneration for their pain treatment (e.g. disability, worker's&#xD;
             compensation, auto injury in litigation or pending litigation).&#xD;
&#xD;
          -  History of prior spine surgery.&#xD;
&#xD;
          -  Grade 2 Spondylolisthesis at an affected or adjacent level.&#xD;
&#xD;
          -  BMI &gt;35.&#xD;
&#xD;
          -  Incarceration.&#xD;
&#xD;
          -  Cognitive deficit affecting ability to complete the assessment instruments.&#xD;
&#xD;
          -  Inability to read English and complete the assessment instruments.&#xD;
&#xD;
          -  Allergy to local anesthetics.&#xD;
&#xD;
          -  Chronic widespread pain or somatoform disorder (e.g. fibromyalgia).&#xD;
&#xD;
          -  Prior lumbar MBN radiofrequency neurotomy.&#xD;
&#xD;
          -  Addictive behavior, severe clinical depression, anxiety, or any mental health&#xD;
             condition with psychotic features.&#xD;
&#xD;
          -  Possible pregnancy or other reason that precludes the use of fluoroscopy.&#xD;
&#xD;
          -  Daily chronic opiate use of &gt;50 morphine equivalents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Utah Orthopaedic Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 12, 2018</study_first_submitted>
  <study_first_submitted_qc>July 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2018</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Zack McCormick</investigator_full_name>
    <investigator_title>Associate Professor, Spine and Pain Medicine Director, Clinical Spine Research Director, Interventional Spine and Musculoskeletal Medicine Fellowship, Division of Physical Medicine and Rehabilitation University of Utah School of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/93/NCT03614793/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

